Buy rather than build from scratch – why acquisitions are often the smarter way

Curaleaf acquired a 55 % majority stake in Four 20 Pharma GmbH, a fully GDP-certified German manufacturer and distributor of medical cannabis.

This 2022 deal shows how a US player enters a new market (in this case the German one) in a targeted way through M&A, rather than starting from scratch.

Why is this acquisition strategically relevant?

✅ Direct market access to the largest medical cannabis market in Europe

✅ A regulatory shortcut thanks to existing certifications

✅ Infrastructure & distribution ready to use immediately

✅ Strong German team + local market knowledge

For Four 20 Pharma, this means: more resources, more international visibility – and the opportunity to keep growing under its own name, but with global tailwind.

⸻

💬 Your opinion?

Will the German cannabis market be dominated by international acquisitions in the future – or can local players survive independently in the long term?

👇 Join the discussion.

#Curaleaf #Four20Pharma #CannabisBusiness #M&A #BuyAndBuild #MedicalCannabis #CannabisGermany #GrowthStrategy #EUmarket #HealthTech #MarketAccess